No abstract available.
Cisplatin*

Experimentation of using Cisplatin produced by Vietnam with dose of LD50=26.00 (23.21-29.12) mg/kg on injection line on peritoneum of white house-mice was monitored for a week, and the 100% mice died. Before the death, the mice often had some kinds of epilepsy. It was proved that this medicine affected on central nervous system. In terms of semi-chronic toxicity, Cisplatin with dose of 0.2mg/kg/24 hours of intravenous injections 5 days per course, with dose of 0.3mg/kg/24 hours of intravenous injection in 5 days, using two courses after 10 days changed some indexes of hematology and microscopic findings of bone marrow. After 15 days to 30 days of discontinuous injection, injuries gradually recovered
Cisplatin ; Cisplatin/toxicity

No abstract available.
Cisplatin* ; Sodium*

No abstract available.
Cisplatin* ; Hearing*

Cisplatin was intravenously injected at the dose of 0.2 mg/kg (equivalent to 1/10 of the maximum non-toxicating dose in mice) four 5-day episodes with the interval of 5 days caused a slight increase in the serum creatinine and urea levels. Similar effects were also observed when cisplatin was IV administered at 0.3 mg/kg/24h for two 5-day episodes with the interval of 10 days. Other mild side effects towards liver and some organs were also observed in about 50% of the mice population. Most of the side effects significantly subdued in both groups 15 days after stopping drug, except damages in hepatic histology, which recovered more slowly
Cisplatin ; Cisplatin/toxicity ; Liver ; Kidney

No abstract available.
Cisplatin* ; Humans ; Nausea* ; Vomiting*

No abstract available.
Cisplatin ; Hyperpigmentation* ; Capecitabine

No abstract available.
Cisplatin* ; Etoposide* ; Ovarian Neoplasms*

No abstract available.
Cisplatin ; Paclitaxel ; Radiodermatitis

OBJECTIVE: The purpose of this study is to determine the time-dependant effects of Glutathione on the Cisplatin-induced cytotoxicity of human cervical carcinoma cells. METHODS: Two human cervical carcinoma cells, SiHa (squamous cell carcinoma cell), and CaSki (epidermoid metastatic carcinoma cell) were cultivated with RPMI1640 media. Reduced glutathione (GSH) and 2-oxo 4-thiazolidine carboxylic acid (OTC) were added one hour before and after Cisplatin (2-50 micro M/ml) was applied. The cells were incubated an additional 24 hours and viable cells were examined using a 3-[4,5- dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) assay. RESULTS: The MTT reduction rate of cisplatin-treated cervical carcinoma cells was increased significantly by the addition of glutathione (5 mM) or OTC (5 mM) both one hour before and after Cisplatin. A difference between MTT reduction rates one hour before and after cisplatin were not observed in either GSH or OTC. CONCLUSION: These results suggest that GSH and OTC have a protective effect on cisplatin-induced toxicity, and that this effect is about the same whether the agents were applied before or after the Cisplatin.
Cisplatin* ; Glutathione* ; Humans*